Pharmacogenetics of breast cancer treatments: a sub-Saharan Africa perspective
KC Nthontho, AK Ndlovu, K Sharma… - Pharmacogenomics …, 2022 - Taylor & Francis
Breast cancer is the most frequent cause of cancer death in low-and middle-income
countries, in particular among sub-Saharan African women, where response to available …
countries, in particular among sub-Saharan African women, where response to available …
Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem, A Mårtensson… - Malaria Journal, 2021 - Springer
Background The anti-malarial drug, amodiaquine, a commonly used, long-acting partner
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
drug in artemisinin-based combination therapy, is metabolized to active desethyl …
[HTML][HTML] Pharmacogenetic considerations in the treatment of co-infections with HIV/AIDS, tuberculosis and malaria in Congolese populations of Central Africa
SR Pallerla, DOE Assiana, FN Cho, CG Meyer… - International Journal of …, 2021 - Elsevier
Background HIV-infection, tuberculosis and malaria are the big three communicable
diseases that plague sub-Saharan Africa. If these diseases occur as co-morbidities they …
diseases that plague sub-Saharan Africa. If these diseases occur as co-morbidities they …
Frequencies of CYP2B6∗ 4,∗ 5, and∗ 6 Alleles within an Iranian Population (Mazandaran)
MB Hashemi-Soteh, E Hosseini, S Fazelnia… - Genetics …, 2021 - cambridge.org
Background. The human CYP2B subfamily consists of one functional gene (CYP2B6) and
one pseudogene (CYP2B7P). Cytochrome P450 2B6 (CYP2B6) is a highly polymorphic …
one pseudogene (CYP2B7P). Cytochrome P450 2B6 (CYP2B6) is a highly polymorphic …
Unanticipated CNS Safety Signal in a Placebo‐Controlled, Randomized Trial of Co‐Administered Atovaquone‐Proguanil and Amodiaquine
S Chalon, MF Chughlay, N Abla… - Clinical …, 2022 - Wiley Online Library
Atovaquone‐proguanil (ATV‐PG) plus amodiaquine (AQ) has been considered as a
potential replacement for sulfadoxine‐pyrimethamine plus AQ for seasonal malaria …
potential replacement for sulfadoxine‐pyrimethamine plus AQ for seasonal malaria …
Human host and malaria parasite genome variations to susceptibility to malaria
H Hordofa - 2023 - open.uct.ac.za
Background: Inter-ethnic differences in response to medication can be explained through
population structure as observed from genetic variants affecting drug metabolism …
population structure as observed from genetic variants affecting drug metabolism …
Clinical probe of Cyp2C8* 2 mutants in a malaria hyperendemic zone: evidence from North-Central, Nigeria
O Shittu, OA Opeyemi, OB Omotesho, O Fakayode… - Acta Medica, 2020 - karolinum.cz
Background: A tremendous level of success has been achieved since the introduction of
chloroquine and the combination of amodiaquine and artemisinin for the treatment of both …
chloroquine and the combination of amodiaquine and artemisinin for the treatment of both …
[PDF][PDF] Influence of Cytochrome P450 (CYP) 2C8 Polymorphisms on the E cacy and Tolerability of Artesunate-Amodiaquine Treatment of Uncomplicated Plasmodium …
L Pernaute-Lau, U Morris, M Msellem, A Mårtensson… - academia.edu
Background The antimalarial drug amodiaquine, a commonly used long acting partner drug
in artemisinin-based combination therapy, is metabolized to active desethyl-amodiaquine …
in artemisinin-based combination therapy, is metabolized to active desethyl-amodiaquine …